AR048269A1 - Compuestos moduladores de receptores opioides - Google Patents
Compuestos moduladores de receptores opioidesInfo
- Publication number
- AR048269A1 AR048269A1 ARP050101007A ARP050101007A AR048269A1 AR 048269 A1 AR048269 A1 AR 048269A1 AR P050101007 A ARP050101007 A AR P050101007A AR P050101007 A ARP050101007 A AR P050101007A AR 048269 A1 AR048269 A1 AR 048269A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- group
- heteroaryl
- alkoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
- C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
Abstract
Métodos para preparar dichos compuestos, composiciones farmacéuticas que los contienen, y uso en el tratamiento de trastorno que se pueden aliviar o tratar mediante la modulacion de los receptores opioides. Reivindicacion 1: Un compuesto de formula (1), donde: R1 se selecciona del grupo que consiste en hidrogeno, alquilo C1-6, cicloalquilo, heterociclilo, (donde el cicloalquilo y heterociclilo está opcionalmente sustituido con uno o dos sustituyentes independientemente seleccionados de alquilo C1-6, hidroxi(alquilo C1-6), alcoxi C1-6, hidroxi, ciano, amino, alquilamino C1-6, (alquil C1-6)2amino, halogeno, carboxi, aril(alcoxi C1-6)carbonilo, alcoxiC1-6carbonilo, aminocarbonilo, alquilC1-6aminocarbonilo, (alquil C1-6)2aminocarbonilo o aminosulfonilo); y además donde arilo está opcionalmente fusionado a un heterociclo o cicloalquilo; donde alquilo C1-6 de R1 está opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionados del grupo que consiste en alcoxiC1-6, arilo, cicloalquilo, heterociclilo, hidroxi, ciano, amino, alquilamino C1-6, (alquil C1-6)2amino, halogeno y carboxi; y donde la porcion arilo y heteroarilo de aril(alquilo C1-6) y heteroaril(alquilo C1-6), respectivamente, están opcionalmente sustituidos con uno a tres sustituyentes independientemente seleccionados de R11, donde R11 es alquilo C1-6, hidroxi(alquilo C1-6), alcoxi C1-6, aril(alquilo C1-6), aril(alcoxi C1-6), arilo, heteroarilo opcionalmente sustituido con alquilo C1-4, cicloalquilo, heterociclilo, ariloxi, heteroariloxi, cicloalquiloxi, heterocicliloxi, amino, alquilamino C1-6, (alquil C1-6)2amino, cicloalquilC1-6aminocarbonilo, hidroxi(alquil C1-6)aminocarbonilo, arilaminocarbonilo, donde arilo está opcionalmente sustituido con carboxi o alcoxiC1-6carbonilo, heterociclilcarbonilo, carboxi, alcoxiC1-6carbonilo, alquilC1-6carbonilo, alquilC1-6carbonilamino, aminocarbonilo, alquilC1-6aminocarbonilo, (alquil C1-6)2aminocarbonilo, ciano, halogeno, trifluorometilo, trifluorometoxi o hidroxi; y donde el arilo en cualquiera de los anteriores sustituyentes de R1 que contienen arilo está opcionalmente fusionado con un heterociclilo o cicloalquilo; R2 es seleccionado del grupo que consiste hidrogeno, alquilo C1-8, hidroxi(alquilo C1-8), aril(alcoxi C1-6)(alquilo C1-6), aril(alquilo C1-8); donde dicho arilo está opcionalmente sustituido con uno a dos sustituyentes independientemente seleccionados del grupo que consiste en alquilo C1-6, alcoxi C1-6, hidroxi, amino, alquilamino C1-6, (alquil C1-6)2amino, aminocarbonilo, alquilC1-6aminocarbonilo, (alquil C1-6)2aminocarbonilo, ciano, fluor, cloro, bromo, trifluorometilo y trifluorometoxi; y donde dichos sustituyentes alquilo y alcoxi de arilo están opcionalmente sustituidos con hidroxi, amino, alquilamino C1-6, (alquil C1-6)2amino o arilo; A se selecciona del grupo que consiste en arilo, el sistema de anillo del resto de grupo de formulas (2), opcionalmente sustituidos con R3 y R5; donde: A-B se selecciona del grupo que consiste en N-C, C-N, N-N y C-C; D-E se selecciona del grupo que consiste en O-C, S-C, y O-N; R3 es uno a dos sustituyentes independientemente seleccionados del grupo que consiste en hidrogeno, alquil C1-6, arilo, aril(alquilo C1-6), aril(alquenilo C2-6), aril(alquinilo C2-6), heteroarilo, heteroaril(alquilo C1-6), heteroaril(alquenilo C2-6), heteroaril(alquinilo C2-6), amino, alquilamino C1-6, (alquil C1-6)2amino, arilamino, heteroarilamino, ariloxi, heteroariloxi y halogeno; donde la porcion arilo y heteroarilo de R3 está opcionalmente sustituida con uno a cinco sustituyentes independientemente seleccionados del grupo que consiste en alquilo C1-6, hidroxi(alquilo C1-6), alcoxi C1-6, aril(alquilo C1-6), aril(alcoxi C1-6), arilo, ariloxi, heteroaril(alquilo C1-6), heteroaril(alcoxi C1-6), heteroarilo, heteroariloxi, arilamino, heteroarilamino, amino, alquilamino C1-6, (alquil C1-6)2amino, carboxi(alquil C1-6)amino, carboxi, alquilC1-6carbonilo, alcoxiC1-6carbonilo, alquilC1-6carbonilamino, aminocarbonilo, alquilC1-6aminocarbonilo, (alquil C1-6)2aminocarbonilo, carboxi(alquil C1-6)aminocarbonilo, ciano, halogeno, trifluorometilo, trifluorometoxi, hidroxi, alquilC1- 6sulfonilo, alquilC1-6sulfonilamino, -C(O)-NH-CH-(-Rc)-C(O)-NH2 y alquilo C1-6; donde alquilo de R3 está opcionalmente sustituido con un sustituyente seleccionado del grupo que consiste en hidroxi, carboxi, alcoxiC1-4carbonilo, amino, alquilamino C1- 6, (alquil C1-6)2amino, aminocarbonilo, (alquil C1-4)aminocarbonilo, di(alquil C1-4)aminocarbonilo, arilo, heteroarilo, arilamino, heteroarilamino, ariloxi, heteroariloxi, aril(alcoxi C1-4) y heteroaril(alcoxi C1-4); Rc se selecciona del grupo que consiste en hidrogeno, alquilo C1-6, alquilC1-6carbonilo, alcoxiC1-6carbonilo, alquilC1-6carbonilamino, aril(alquilo C1-6), heteroaril(alquilo C1-6), arilo, y heteroarilo; R4 es arilo o heteroarilo; donde R4 está opcionalmente sustituido con uno a cinco sustituyentes independientemente seleccionados del grupo R41; donde R41 es alquilo C1-6, alcoxi C1-6, aril(alcoxi C1-6), aril(alquil C1-6)carboniloxi, heteroaril(alquil C1-6)carboniloxi, heteroarilo, hidroxi, halogeno, aminosulfonilo, formilamino, aminocarbonilo, alquilC1-6aminocarbonilo, (alquil C1-6)2aminocarbonilo, heterociclilcarbonilo, carboxi, o ciano; y donde alquilo C1-6 está opcionalmente sustituido con amino, alquilC1-6amino, o (alquil C1-6)2amino; y donde la porcion arilo de aril(alquil C1-6)carboniloxi está opcionalmente sustituida con uno a cuatro sustituyentes independientemente seleccionados del grupo que consiste en alquilo C1-6, alcoxi C1-6, halogeno, ciano, amino, e hidroxi; R5 es un sustituyente en un átomo de nitrogeno contenido en un anillo ha seleccionado del grupo que consiste en hidrogeno, alquilo C1-4 y arilo; R6 se selecciona del grupo que consiste en hidrogeno y alquilo C1-6; R7 se selecciona del grupo que consiste en hidrogeno y alquilo C1-6; Ra y Rb son sustituyentes independientemente seleccionados del grupo que consiste en hidrogeno y alquilo C16; o Ra y Rb, cuando son distintos de hidrogeno, se toman junto con el nitrogeno al que ambos están unidos para formar un anillo monocíclico de cinco a ocho miembros; L se selecciona del grupo que consiste en O, S y N(Rd); donde Rd es hidrogeno, alquilo C1-6 o arilo; y enantiomeros, diastereomeros, racematos aceptables para uso farmacéutico, y sales de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55334204P | 2004-03-15 | 2004-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR048269A1 true AR048269A1 (es) | 2006-04-12 |
Family
ID=34962827
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050101007A AR048269A1 (es) | 2004-03-15 | 2005-03-15 | Compuestos moduladores de receptores opioides |
ARP140101566A AR095848A2 (es) | 2004-03-15 | 2014-04-11 | Derivados imidazolicos de propionamida moduladores de receptores opioides |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140101566A AR095848A2 (es) | 2004-03-15 | 2014-04-11 | Derivados imidazolicos de propionamida moduladores de receptores opioides |
Country Status (36)
Country | Link |
---|---|
US (8) | US7741356B2 (es) |
EP (5) | EP3112352B1 (es) |
JP (1) | JP4778954B2 (es) |
KR (1) | KR101166342B1 (es) |
CN (2) | CN102786476B (es) |
AR (2) | AR048269A1 (es) |
AT (1) | ATE516274T1 (es) |
AU (1) | AU2005224091B2 (es) |
BR (1) | BRPI0508820B8 (es) |
CA (1) | CA2560047C (es) |
CR (1) | CR8655A (es) |
CY (3) | CY1111927T1 (es) |
DK (5) | DK2298744T3 (es) |
EC (1) | ECSP066856A (es) |
ES (5) | ES2596434T3 (es) |
HK (4) | HK1099016A1 (es) |
HR (4) | HRP20110694T1 (es) |
HU (2) | HUE029852T2 (es) |
IL (3) | IL178040A (es) |
LT (2) | LT2653465T (es) |
LU (1) | LUC00007I2 (es) |
ME (3) | ME02540B (es) |
MX (1) | MXPA06010642A (es) |
MY (1) | MY146972A (es) |
NL (1) | NL300865I2 (es) |
NO (3) | NO338203B1 (es) |
NZ (1) | NZ549842A (es) |
PH (1) | PH12012501640A1 (es) |
PL (4) | PL2573068T3 (es) |
PT (4) | PT2298744E (es) |
RS (4) | RS52933B (es) |
SI (4) | SI1725537T1 (es) |
TW (1) | TWI361069B (es) |
UA (1) | UA86053C2 (es) |
WO (1) | WO2005090315A1 (es) |
ZA (1) | ZA200608587B (es) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
SI1725537T1 (sl) | 2004-03-15 | 2011-11-30 | Janssen Pharmaceutica Nv | Nove spojine kot modulatorji opioidnih receptorjev |
NZ551288A (en) | 2004-05-14 | 2010-10-29 | Janssen Pharmaceutica Nv | Carboxamido opioid compounds that are derivatives of tramadol |
JP2008523815A (ja) | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミテッド | 認知の改善における使用のためのヒト化アミロイドβ抗体 |
CA2601674A1 (en) * | 2005-03-14 | 2006-09-21 | Janssen Pharmaceutica N.V. | Process for the preparation of opioid modulators |
WO2007070826A1 (en) * | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors |
CN102690221B (zh) * | 2005-12-23 | 2014-12-03 | 西兰岛药物有限公司 | 改性的拟赖氨酸化合物 |
KR20080113275A (ko) | 2006-04-07 | 2008-12-29 | 더 프록터 앤드 갬블 캄파니 | 인간 단백질 타이로신 포스파타아제 베타(hptp베타)에 결합하는 항체 및 그의 용도 |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
DK2468724T3 (en) | 2006-12-21 | 2016-02-22 | Zealand Pharma As | Synthesis of pyrrolidine compounds |
CN101730685A (zh) | 2007-07-09 | 2010-06-09 | 詹森药业有限公司 | 5-({[2-氨基-3-(4-氨甲酰基-2,6-二甲基-苯基)-丙酰基]-[1-(4-苯基-1h-咪唑-2-基)-乙基]-氨基}-甲基)-2-甲氧基-苯甲酸的新型晶体及其制备方法 |
ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
TWI468375B (zh) * | 2008-10-27 | 2015-01-11 | Janssen Pharmaceutica Nv | 製備經保護之l-丙胺酸衍生物之方法 |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
JP5198220B2 (ja) * | 2008-11-13 | 2013-05-15 | 東ソ−・エフテック株式会社 | アミノ酸誘導体の製造方法 |
PL2451279T3 (pl) | 2009-07-06 | 2019-09-30 | Aerpio Therapeutics, Inc. | Pochodne benzosulfonamidowe, ich kompozycje i ich zastosowanie w zapobieganiu przerzutom komórek nowotworowych |
US9493451B2 (en) | 2011-05-16 | 2016-11-15 | Bionomics Limited | Amine derivatives as potassium channel blockers |
EP2524912A1 (en) | 2011-05-16 | 2012-11-21 | Bionomics Limited | Amine derivatives |
EP3505182A1 (en) | 2011-10-13 | 2019-07-03 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome and cancer |
US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP2970135B1 (en) | 2013-03-14 | 2018-07-18 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
KR102028793B1 (ko) | 2013-03-14 | 2019-10-07 | 에피자임, 인코포레이티드 | 아르기닌 메틸기 전이효소 억제제 및 이의 용도 |
US9675587B2 (en) * | 2013-03-14 | 2017-06-13 | Allergan Holdings Unlimited Company | Opioid receptor modulator dosage formulations |
EP2970133B1 (en) * | 2013-03-14 | 2018-10-24 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
WO2015138882A1 (en) | 2014-03-14 | 2015-09-17 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
IS2977B (is) | 2015-02-23 | 2017-07-15 | Actavis Group Ptc Ehf. | Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni |
WO2017007695A1 (en) | 2015-07-09 | 2017-01-12 | The Regents Of The University Of California | Mu opioid receptor modulators |
US10314819B2 (en) | 2015-07-23 | 2019-06-11 | Teva Pharmaceuticals International Gmbh | Solid state forms of Eluxadoline |
WO2017043626A1 (ja) * | 2015-09-11 | 2017-03-16 | 株式会社カネカ | 光学活性4-カルバモイル-2,6-ジメチルフェニルアラニン誘導体の製造法 |
BR112018005499A2 (pt) | 2015-09-23 | 2018-10-09 | Aerpio Therapeutics Inc | métodos de tratamento de pressão intraocular com ativadores de tie-2. |
CN105250232B (zh) * | 2015-09-29 | 2018-08-14 | 江苏汇智知识产权服务有限公司 | 一种伊卢多啉肠溶片及其制备方法 |
WO2017114446A1 (zh) * | 2015-12-31 | 2017-07-06 | 苏州晶云药物科技有限公司 | 艾沙度林的新晶型及其制备方法 |
CN107129444B (zh) * | 2016-02-29 | 2018-08-31 | 尚科生物医药(上海)有限公司 | (s)-2-叔丁氧羰基氨基-3-(4-氨甲酰基-2,6-二甲基苯基)丙酸制备方法 |
EP3272741A1 (en) | 2016-07-21 | 2018-01-24 | Euticals S.P.A. | New stable solvate crystalline forms of eluxadoline |
CN105777584B (zh) * | 2016-03-28 | 2018-01-02 | 成都伊诺达博医药科技有限公司 | 丙氨酸衍生物的制备方法 |
CN105693554B (zh) * | 2016-04-06 | 2017-08-08 | 成都伊诺达博医药科技有限公司 | 丙氨酸衍生物的制备方法 |
US20190177281A1 (en) * | 2016-05-03 | 2019-06-13 | Sromovasam THIRUMALAI RAJAN | Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl] [(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino] methyl-2-methoxybenzoic acid and its polymorphs thereof |
MA45184A (fr) * | 2016-05-30 | 2019-04-10 | Sun Pharmaceutical Ind Ltd | Procédé de préparation de l'éluxadoline . |
EP3474847B1 (en) * | 2016-06-23 | 2022-09-07 | Sun Pharmaceutical Industries Limited | Processes for the preparation of eluxadoline |
WO2018020450A2 (en) | 2016-07-28 | 2018-02-01 | Lupin Limited | Process for the preparation of eluxadoline |
CZ2016548A3 (cs) | 2016-09-07 | 2018-03-14 | Zentiva, K.S. | Pevné formy eluxadolinu |
WO2018047131A1 (en) * | 2016-09-09 | 2018-03-15 | Sun Pharmaceutical Industries Limited | Amorphous eluxadoline |
US10479769B2 (en) | 2016-09-20 | 2019-11-19 | Sun Pharmaceutical Industries Limited | Processes for the preparation of eluxadoline |
WO2018138272A1 (en) | 2017-01-27 | 2018-08-02 | Quimica Sintetica, S. A. | Eluxadoline crystalline form and process for the preparation thereof |
EP3573958A1 (en) | 2017-01-27 | 2019-12-04 | Quimica Sintetica, S.A. | Eluxadoline crystalline forms and processes for their preparation |
EP3618847B1 (en) | 2017-05-05 | 2021-04-07 | Zealand Pharma A/S | Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease |
WO2019008604A1 (en) | 2017-07-07 | 2019-01-10 | Cipla Limited | NEW FORMS OF MU-OPIOID RECEPTOR AGONIST |
WO2019144805A1 (zh) * | 2018-01-25 | 2019-08-01 | 四川科伦博泰生物医药股份有限公司 | 取代的苯乙胺化合物及其制备方法和用途 |
WO2019197274A1 (en) | 2018-04-09 | 2019-10-17 | Quimica Sintetica, S. A. | Process for the preparation of opioid modulators |
CA3109557A1 (en) | 2018-08-20 | 2020-02-27 | Allergan Holdings Unlimited Company | Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
JP2022502367A (ja) | 2018-09-24 | 2022-01-11 | エアーピオ ファーマシューティカルズ, インコーポレイテッド | HPTP−β(VE−PTP)およびVEGFを標的にする多特異性抗体 |
PL3659433T3 (pl) * | 2018-11-30 | 2021-11-08 | Phytobiotics Futterzusatzstoffe Gmbh | System analizowania obrazów wydzielin zwierzęcych |
CN111377832A (zh) * | 2018-12-27 | 2020-07-07 | 江苏联昇化学有限公司 | 一种伊卢多啉中间体制备的新方法 |
EP3962482A4 (en) | 2019-04-29 | 2023-01-11 | EyePoint Pharmaceuticals, Inc. | TIE-2 ACTIVATORS TARGETING THE SCHLEMM CHANNEL |
US20230118152A1 (en) | 2020-03-30 | 2023-04-20 | Allergan Holdings Unlimited Company | Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid |
CN116348465A (zh) * | 2020-07-28 | 2023-06-27 | 爵士制药爱尔兰有限公司 | 稠合双环raf抑制剂的手性合成 |
US20220096676A1 (en) | 2020-09-29 | 2022-03-31 | Abl Ip Holding Llc | Techniques for Directing Ultraviolet Energy Towards a Moving Surface |
US11850319B2 (en) | 2020-09-29 | 2023-12-26 | Abl Ip Holding Llc | Techniques for directing ultraviolet energy towards a moving surface |
CN114163348A (zh) * | 2020-11-27 | 2022-03-11 | 成都泰蓉生物科技有限公司 | 一种氨酰基取代的l-苯丙氨酸的合成方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD142804A3 (de) * | 1977-11-07 | 1980-07-16 | Wagner Guenter | Verfahren zur herstellung von na-alkyl-bzw.na-aryl-sulfonylierten omega-amidinophenyl-alpha-aminoalkylcarbonsaeureamiden |
US4879398A (en) * | 1987-12-31 | 1989-11-07 | Monsanto Company | Process for producing 2,6-disubstituted tyrosine |
SE9402880D0 (sv) | 1994-08-30 | 1994-08-30 | Astra Ab | New peptide derivatives |
WO1996022997A1 (en) | 1995-01-27 | 1996-08-01 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
US5565568A (en) | 1995-04-06 | 1996-10-15 | Eli Lilly And Company | 2-acylaminopropanamides as tachykinin receptor antagonists |
AU700693B2 (en) | 1995-04-13 | 1999-01-14 | Aventis Pharmaceuticals Inc. | Novel substituted piperazine derivatives having tachykinin receptor antagonists activity |
WO1997006803A1 (en) | 1995-08-21 | 1997-02-27 | Eli Lilly And Company | 2-acylaminopropanamides as growth hormone secretagogues |
WO1997019908A1 (en) | 1995-11-29 | 1997-06-05 | Nihon Nohyaku Co., Ltd. | Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides |
US5792760A (en) | 1997-04-23 | 1998-08-11 | Eli Lilly And Company | Bisindoles as tachykinin receptor antagonists |
IT1304898B1 (it) | 1998-09-08 | 2001-04-05 | Menarini Ricerche Spa | Prodotti con caratteristiche basiche aventi attivita' antagonista sulrecettore nk-1 e loro impiego in preparazioni farmaceutiche |
ES2206139T3 (es) * | 1999-05-28 | 2004-05-16 | Pfizer Products Inc. | Derivados de 3-(3-hidrofenil)-3-amino-propionamida. |
FR2796643B1 (fr) | 1999-07-22 | 2005-04-29 | Sod Conseils Rech Applic | Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique |
GB0021419D0 (en) | 2000-08-31 | 2000-10-18 | Oxford Glycosciences Uk Ltd | Compounds |
US20020072017A1 (en) * | 2000-10-19 | 2002-06-13 | Hudnall Phillip Montgomery | Stabilized p-phenylenediamine-type photographic color developers in free base form |
CZ20031422A3 (cs) | 2000-10-30 | 2004-01-14 | Janssen Pharmaceutica N. V. | Inhibitory tripeptidylpeptidázy |
JP4417108B2 (ja) * | 2001-10-15 | 2010-02-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 新規な置換された4−フェニル−4−[1h−イミダゾール−2−イル]−ピペリジン誘導体および選択的非ペプチドデルタオピオイドアゴニストとしてのそれらの使用 |
US7041681B2 (en) * | 2002-04-29 | 2006-05-09 | Janssen Pharmaceutica N.V. | Compounds as opioid receptor modulators |
SI1725537T1 (sl) * | 2004-03-15 | 2011-11-30 | Janssen Pharmaceutica Nv | Nove spojine kot modulatorji opioidnih receptorjev |
US7282507B2 (en) | 2004-05-03 | 2007-10-16 | Janssen Pharmaceutica N.V. | Indole derivatives as selective androgen receptor modulators (SARMS) |
CA2601674A1 (en) * | 2005-03-14 | 2006-09-21 | Janssen Pharmaceutica N.V. | Process for the preparation of opioid modulators |
-
2005
- 2005-03-14 SI SI200531383T patent/SI1725537T1/sl unknown
- 2005-03-14 SI SI200531771T patent/SI2298744T1/sl unknown
- 2005-03-14 LT LTEP13173454.3T patent/LT2653465T/lt unknown
- 2005-03-14 PL PL12194058T patent/PL2573068T3/pl unknown
- 2005-03-14 ES ES13173454.3T patent/ES2596434T3/es active Active
- 2005-03-14 AT AT05728171T patent/ATE516274T1/de active
- 2005-03-14 SI SI200531934T patent/SI2573068T1/sl unknown
- 2005-03-14 UA UAA200609824A patent/UA86053C2/ru unknown
- 2005-03-14 ME MEP-2016-232A patent/ME02540B/me unknown
- 2005-03-14 PT PT101823490T patent/PT2298744E/pt unknown
- 2005-03-14 PL PL13173454T patent/PL2653465T3/pl unknown
- 2005-03-14 DK DK10182349.0T patent/DK2298744T3/da active
- 2005-03-14 CN CN201210277845.6A patent/CN102786476B/zh not_active Expired - Fee Related
- 2005-03-14 TW TW094107612A patent/TWI361069B/zh not_active IP Right Cessation
- 2005-03-14 CN CN200580014571XA patent/CN1950342B/zh not_active Expired - Fee Related
- 2005-03-14 SI SI200532091A patent/SI2653465T1/sl unknown
- 2005-03-14 PL PL10182349T patent/PL2298744T3/pl unknown
- 2005-03-14 BR BRPI0508820A patent/BRPI0508820B8/pt not_active IP Right Cessation
- 2005-03-14 EP EP16178050.7A patent/EP3112352B1/en active Active
- 2005-03-14 ME MEP-2015-36A patent/ME02221B/me unknown
- 2005-03-14 ES ES16178050T patent/ES2705077T3/es active Active
- 2005-03-14 RS RS20130371A patent/RS52933B/en unknown
- 2005-03-14 CA CA2560047A patent/CA2560047C/en active Active
- 2005-03-14 ES ES05728171T patent/ES2367576T3/es active Active
- 2005-03-14 EP EP12194058.9A patent/EP2573068B9/en active Active
- 2005-03-14 PT PT121940589T patent/PT2573068E/pt unknown
- 2005-03-14 AU AU2005224091A patent/AU2005224091B2/en not_active Ceased
- 2005-03-14 KR KR1020067021231A patent/KR101166342B1/ko active IP Right Grant
- 2005-03-14 MY MYPI20051060A patent/MY146972A/en unknown
- 2005-03-14 EP EP05728171A patent/EP1725537B1/en active Active
- 2005-03-14 ME MEP-2013-97A patent/ME01601B/me unknown
- 2005-03-14 EP EP10182349.0A patent/EP2298744B1/en active Active
- 2005-03-14 PL PL05728171T patent/PL1725537T3/pl unknown
- 2005-03-14 NZ NZ549842A patent/NZ549842A/en not_active IP Right Cessation
- 2005-03-14 DK DK05728171.9T patent/DK1725537T3/da active
- 2005-03-14 DK DK16178050.7T patent/DK3112352T3/en active
- 2005-03-14 RS RS20160843A patent/RS55122B1/sr unknown
- 2005-03-14 HU HUE13173454A patent/HUE029852T2/en unknown
- 2005-03-14 MX MXPA06010642A patent/MXPA06010642A/es active IP Right Grant
- 2005-03-14 US US11/079,647 patent/US7741356B2/en active Active
- 2005-03-14 DK DK12194058.9T patent/DK2573068T3/en active
- 2005-03-14 DK DK13173454.3T patent/DK2653465T3/da active
- 2005-03-14 WO PCT/US2005/008339 patent/WO2005090315A1/en active Application Filing
- 2005-03-14 PT PT05728171T patent/PT1725537E/pt unknown
- 2005-03-14 ES ES12194058.9T patent/ES2533176T3/es active Active
- 2005-03-14 RS RS20150204A patent/RS54199B1/en unknown
- 2005-03-14 ES ES10182349T patent/ES2428008T3/es active Active
- 2005-03-14 EP EP13173454.3A patent/EP2653465B1/en active Active
- 2005-03-14 JP JP2007503986A patent/JP4778954B2/ja not_active Expired - Fee Related
- 2005-03-14 RS RS20110446A patent/RS51995B/en unknown
- 2005-03-14 PT PT131734543T patent/PT2653465T/pt unknown
- 2005-03-15 AR ARP050101007A patent/AR048269A1/es active IP Right Grant
-
2006
- 2006-09-12 IL IL178040A patent/IL178040A/en active IP Right Grant
- 2006-09-15 EC EC2006006856A patent/ECSP066856A/es unknown
- 2006-09-25 CR CR8655A patent/CR8655A/es unknown
- 2006-10-13 ZA ZA2006/08587A patent/ZA200608587B/en unknown
- 2006-10-13 NO NO20064660A patent/NO338203B1/no not_active IP Right Cessation
-
2007
- 2007-05-28 HK HK07105593.3A patent/HK1099016A1/xx not_active IP Right Cessation
- 2007-10-17 HK HK07111210.4A patent/HK1105967A1/xx not_active IP Right Cessation
- 2007-10-24 US US11/877,747 patent/US7786158B2/en active Active
-
2010
- 2010-07-19 US US12/838,825 patent/US8344011B2/en active Active
-
2011
- 2011-09-19 HK HK11109830.2A patent/HK1155726A1/xx not_active IP Right Cessation
- 2011-09-28 HR HR20110694T patent/HRP20110694T1/hr unknown
- 2011-10-10 CY CY20111100967T patent/CY1111927T1/el unknown
-
2012
- 2012-08-14 PH PH12012501640A patent/PH12012501640A1/en unknown
- 2012-11-30 US US13/690,041 patent/US8609709B2/en active Active
-
2013
- 2013-02-26 IL IL224908A patent/IL224908A/en active IP Right Grant
- 2013-08-22 HR HRP20130800TT patent/HRP20130800T1/hr unknown
- 2013-09-27 HK HK13111031.3A patent/HK1184432A1/xx not_active IP Right Cessation
- 2013-10-03 US US14/045,008 patent/US8772325B2/en active Active
- 2013-11-14 IL IL229444A patent/IL229444A/en active IP Right Grant
-
2014
- 2014-04-11 AR ARP140101566A patent/AR095848A2/es unknown
- 2014-05-20 US US14/282,828 patent/US9205076B2/en active Active
-
2015
- 2015-03-18 HR HRP20150305TT patent/HRP20150305T1/hr unknown
- 2015-10-12 US US14/880,597 patent/US9700542B2/en active Active
-
2016
- 2016-05-30 NO NO20160916A patent/NO20160916A1/no not_active Application Discontinuation
- 2016-10-12 HR HRP20161331TT patent/HRP20161331T1/hr unknown
- 2016-10-12 CY CY20161101019T patent/CY1118096T1/el unknown
-
2017
- 2017-02-23 NO NO2017007C patent/NO2017007I1/no unknown
- 2017-03-01 LU LU00007C patent/LUC00007I2/fr unknown
- 2017-03-01 LT LTPA2017005C patent/LTC1725537I2/lt unknown
- 2017-03-02 HU HUS1700010C patent/HUS1700010I1/hu unknown
- 2017-03-08 CY CY2017008C patent/CY2017008I1/el unknown
- 2017-03-10 NL NL300865C patent/NL300865I2/nl unknown
- 2017-06-07 US US15/616,358 patent/US10213415B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR048269A1 (es) | Compuestos moduladores de receptores opioides | |
AR069512A1 (es) | Pirazolopirimidinas sustituidas para el tratamiento de trastornos del snc. composiciones farmaceuticas | |
AR047537A1 (es) | Piridazinonaureas como antagonistas de integrinas | |
AR076198A1 (es) | Derivados herbicidas de oxopiridina y tionopiridina | |
AR043938A1 (es) | Compuesto heterociclico derivado de quinolina o naftiridina, composicion farmaceutica que lo comprende y su uso para preparar esta ultima | |
AR034127A1 (es) | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento | |
AR058287A1 (es) | Derivados de isoquinolina y composicion farmaceutica | |
AR058587A1 (es) | Compuestos de pirrolo-1,5-naftiridinona,su uso como agentes antibacterianos, composiciones farmaceuticas que los contienen y compuestos intermediarios para preparar dichos compuestos | |
AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
PE20191147A1 (es) | Modulador de regulador de conductancia de transmembrana de fibrosis quistica, composiciones farmaceuticas, metodos de tratamiento y proceso para producir el modulador | |
AR049699A1 (es) | Derivados de pirimidina | |
AR082799A1 (es) | Derivados de quinolina y quinoxalina como inhibidores de quinasa | |
PE20141582A1 (es) | Pirimidinas anilladas sustituidas y uso de las mismas | |
AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
AR056536A1 (es) | Compuestos de 2-amino-5- [4-(difluormetoxi)fenil]-5-fenilimidazolona como inhibidores de la beta secretasa (bace) | |
AR062209A1 (es) | Pirazolopirimidinas moduladoras de receptores de glutamato metabotropicos mglur5, proceso para su preparacion, medicamentos que las contienen y usos en la prevencion y/o tratamiento de trastornos neurologicos agudos y cronicos. | |
AR068061A1 (es) | Derivados de bisamida biciclicos utiles como pesticidas | |
JP2016522172A5 (es) | ||
AR066111A1 (es) | Compuesto triciclico de imidazol, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios en la sintesis de dicho compuesto | |
AR053195A1 (es) | Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo | |
AR070998A1 (es) | Derivados de naftiridina, un procedimiento para su preparacion y la de sus intermediarios de sintesis, una composicion herbicida que los comprende y un metodo para controlar malezas selectivamente que los emplea. | |
AR073498A1 (es) | Derivados de tieno [2-3-d] pirimidin | |
AR050617A1 (es) | Derivados de pirimidin sulfonamidas como moduladores de receptores de quimioquinas | |
AR060287A1 (es) | Compuesto de 5,6 dihidro-3h-pirrolo[1,2,3-de]quinoxalini-3-ona, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y compuesto intermediario util para su preparacion | |
AR069691A1 (es) | Derivados ciclopropilamina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |